Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Antibody generation is the production of antibodies from cells or animals in sufficient quantity to be used as an experimental or therapeutic reagent. Polyclonal antibody mixtures are generated by injecting an animal with an agent that elicits an immune response, and monoclonal antibodies are generated from immortal immune cell lines.
A computational method for the systematic grafting of animal complementarity-determining regions onto thousands of human frameworks allows for the design of humanized versions of antibodies with improved stability.
The covid pandemic has highlighted the need for rapid antibody development. Here, authors develop an approach called SLISY, which uses NGS with phage display to simultaneously assess millions of clones to rapidly isolate specific antibodies against SARS-CoV-2 and its evolving variants.
SARM1 is a key player in axon degeneration. Here, the authors generate a nanobody, which specifically recognizes the NMN-bound state of SARM1 and helps resolve the SARM1 structure in an intermediate state of activation.
A novel bright near-infrared fluorescent protein inserted into a nanobody enables visualization of native proteins inside living cells and specific manipulation of cell function, including Boolean protein-based operators.
